INTRODUCTION

The use of cyclodextrins (CDs) for the solubilization, stabilization and formulation of drugs through the formation of inclusion complexes, while summarized findings on the safety profile of CDs. Numerous other major reviews have been published on the current and potential uses of CDs. Many new, and many more old, generic drugs need appropriate formulation, better than what was considered satisfactory some years ago. The search for new drugs (which exponentially rising expense) continues, but the search for new formulations (which are less expensive) resulting in more stable preparations with better bioavailability properties, allowing the design of new, and more effective drug delivery systems, is increasing more rapidly. This provides the main impetus for the research into CD-drug combinations. Investigations into bioavailability increase comprise one of the dynamically developing fields of drug research. While studies on the bioavailability of drugs from a given dosage form have revealed that in many situations various dosage forms with the same content of active substance did not give the same therapeutic effect control of the bioavailability of drugs is a major requirement in drug production, especially for drugs of very low water solubility. This work is based on the investigation of gemfibrozil (GEM), which has a lipid-regulating pharmaceutical effect, and its solubility properties, with a view to improving the bioavailability of GEM, and therefore decreasing its dose and side effects.

The main line of my experiments is in vitro availability studies, and some other examinations suitable for the evaluation of complex formation. In several cases, I have formulated complete solid dosage forms (tablets and capsules), where the in vitro availability is better than that of the official dosage forms.

OBJECTIVES

The investigation of the following phenomena were the objectives of my Ph.D. research:

- Investigation of the solubility increasing effect of different CD-derivatives and selection of the proper complex forming agent of GEM + dimethyl-β-cyclodextrin (DIMEB);
- Preparation of products with selected CD-derivatives (DIMEB) in different ratios and methods of preparation;
- Determination of the products (inclusion complexes) of the following studies:
  - Phase solubility diagram,
  - Solubility and dissolution rate,
In vitro membrane diffusion kinetics, 
n-octanol/water partition coefficient, 
Thermoanalytical investigations (TG, DTG, DTA, and DSC), 
FT-IR, $^1$H NMR, and X-ray powder diffraction investigations;

- Powder technological investigations:
  - Partial size distribution,
  - SEM investigation of the complex surface,
  - Contact wetting angles determination;

- Preparation of solid dosage forms from 1:2 GEM + DIMEB kneaded product (capsules and tablets);
- Examinations of capsules and tablets.

**MATERIALS AND METHODS**

**Gemfibrozil** is 2,2-dimethyl-5-(2,5-xylyloxy)valeric acid (Fig. 1), (Plantex Chemicals, Israel, API Division Teva Group).

![Chemical structure of GEM](image)

**Fig. 1. Chemical structure of GEM**

**Description:** the empirical formula is $C_{15}H_{22}O_3$ and the molecular weight is 250.35. The solubility in water and acid is 0.0019 % and in dilute base it is greater than 1%. The melting point is 58–61°C. GEM is a white waxy crystalline solid powder, which is stable under ordinary conditions. It is a lipid-regulating agent. It is available as tablets (LOPID®, INNOGEM®, MINILIP®) for oral administration. Each tablet contains 300 or 600 mg GEM.

**Cyclodextrins:** α-CD, β-CD, γ-CD, hydroxybutenyl-β-CD (HBU-β-CD), 2-hydroxypropyl-β-CD (HP-β-CD), heptakis-2,6-di-O-methyl-β-CD (DIMEB), and randomly methylated-β-CD (RAMEB) (Cyclolab R&D Laboratory Ltd., Hungary); Captisol® (Cydex, Inc., USA).

**Other materials:** Microcrystalline cellulose (Avicel PH 101) (FMC Corp., USA), lactose, magnesium stearate and talc (Ph. Eur. 4th); sodium starch glycolate (VIVASTAR®) (J. Rettenmaier and Söhne GmbH, Germany); silicified microcrystalline cellulose (Prosolv SMCC™ 50) (England), n-octanol (Molar Chemicals Kft., Hungary), disodium-hydrogen-
phosphate, potassium dihydrogenphosphate, sodium chloride, glycine, and hydrochloric acid (Reanal Co., Hungary).

**Methods**

**Preparation of products**

Products were prepared in four different molar ratios (GEM+CD molar ratio = 2:1, 1:1, 1:2 and 1:3). *Physical mixtures (PMs)*: the pure drug and CD were mixed in a mortar and sieved through a 100 µm sieve. *Kneaded products (KPs)*: PMs of the drug and DIMEB were mixed (Erweka LK5) with the same quantity of a solvent mixture of ethanol + water (1:1). They were kneaded until the bulk of the solvent mixture had evaporated. After this they were dried at room temperature and were then pulverized and sieved through a 100 µm sieve. *Spray-dried products (SDs)*: the PMs of GEM and DIMEB were dissolved in 50% ethanol. The SDs were obtained by using a Büchi Mini Dryer B-191, with compressed air flow: 800 L/min at 75 °C inlet temperature, and nozzle diameter: 0.5 mm. The aspirator rate was 75–80%, and the pump rate was 3–7%. *Products prepared by ultrasound treatment (USs)*: GEM and DIMEB with different molar ratios of PMs were dissolved in 50% ethanol and mixed to obtain clear solutions, then placed in the ultrasound apparatus for 1 h, dried at room temperature, pulverized and sieved through a 100 µm sieve.

Products were stored under normal conditions at room temperature in well-closed glass containers.

**Preparation of solid dosage forms**

The powder components (except the magnesium stearate) were measured and mixed for 8 min (50 rpm) in a Turbula mixer (WAB Turbula, Switzerland). Homogenization was repeated after the addition of magnesium stearate (2 min). The moisture contents of the GEM+DIMEB 1:2 KP and the homogeneous PM were determined in 3 parallel measurement (Mettler Toledo HR 73 Halogen Moisture Analyzer, Mettler-Toledo GmbH, Switzerland).

Tabletting was carried out with a Korsch EK 0 eccentric tablet machine (E. Korsch Maschinenfabrik, Germany).

The hard gelatin capsules were prepared with the ZUMA semiautomatic capsule-filling machine (150 A/4 with 150/B-3, Zuma S.r.L., Italy). Prosolv SMCC™ 50 with good flowability was used as filler. The calculated quantities of the components were measured and homogenized with a Turbula mixer for 10 min. The capsules were white.
hydroxypropylmethyl cellulose (HPMC) hard ones (size 2) (Syntapharma, GES für Pharmachemie mbH). The dissolution and *in vitro* membrane diffusion results of the 1:2 product gave the basis for the determination of the active agent content. Tablets and capsules containing 8.84 mg active agent were prepared. Literature data from previous studies, book, etc. were used when the auxiliary materials were selected for tabletting and also in the choice of the tabletting methodology, the composition of the tablets and capsules are presented in the following table:

<table>
<thead>
<tr>
<th>Components</th>
<th>Tablet</th>
<th>Capsule</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg</td>
<td>%</td>
</tr>
<tr>
<td>1:2 KP (GEM + DIMEB)</td>
<td>89.50</td>
<td>49.73</td>
</tr>
<tr>
<td>Avicel PH 101</td>
<td>54.00</td>
<td>30.00</td>
</tr>
<tr>
<td>Lactose</td>
<td>30.20</td>
<td>16.77</td>
</tr>
<tr>
<td>Talc</td>
<td>3.60</td>
<td>2.00</td>
</tr>
<tr>
<td>Vivastar®</td>
<td>1.80</td>
<td>1.00</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>0.90</td>
<td>0.50</td>
</tr>
<tr>
<td>Prosolv SMCC™ 50</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Average mass</td>
<td>180.00</td>
<td>100.00</td>
</tr>
</tbody>
</table>

**RESULTS AND DISCUSSION**

The aim of this work was to assess the ability of DIMEB to form inclusion compounds of gemfibrozil. This will permit establishment of the best vehicle for GEM preformulation in order to enhance its solubility and bioavailability, the possibility, that the molecule size and the structure allow the material to form inclusion complex with CDs, and promising a decrease in the therapeutic dose.

My work can be summarized as following:

*In vitro availability investigation result*

Solubility increasing effect of the available CD derivatives was determined in uniform conditions. It was established, that the solubility of the active ingredients were always higher with CDs (except the GEM and DIMEB). Fig. 2. show phase solubility equilibrium diagram for the GEM + DIMEB system in water 25 °C. The solubility of GEM increased linearly in
the presence of this CD derivatives (see Table 2). The variable of the solubility increasing values were high enough (2.5 mg/100ml to 65.5 mg/100ml increased the solubility).

\[ y = 0.0065x - 0.0795 \]
\[ R^2 = 0.9966 \]

![Diagram of increasing solubility of GEM+CD-derivatives in water at 25 °C](image)

In the past few decades, the pharmaceutical modification of drug molecules by inclusion complexation has been extensively developed to improve their dissolution rate, chemical stability, absorption and bioavailability. In this respect, cyclodextrins have received an increasing attention in the pharmaceutical field, and there is no doubt that the determination of dissolution rates is an important tool in the development, evaluation, and control of solid dosage forms. The DIMEB showed the highest solubility-increasing effect on the solubility of GEM (see Table 2.), were the dissolution of the products was better than that of the pure drug, the dissolution rate depended on the CD content. The GEM dissolves sparingly in SGM: only 2.6 mg /100 mL dissolved during the 2 h investigation period. The solubility is better in SIM, as a result of its chemical nature: 38.0 mg dissolves in 100 mL acceptor phase in 2 h. The dissolution of the CD-containing products was in all cases better than that of the pure drug. A 3–6-fold solubility increase was measured depending on the preparation methodology (e.g. see Fig. 3 and 4).
Some of the products dissolved totally in the small volume of acceptor phase, in spite of the increased GEM content of the product. Therefore, the saturation concentration was determined for all of the products. The results for the SDs as an example (see Fig. 5).
The *in-vitro* membrane-diffusion 3–5-fold increased from SGM, whereas from SIM was to the same extent (see Fig. 6, 7). The amount diffused of drug through the membrane into simulated plasma medium during 150 min under *in vitro* conditions, was not dependent on the composition of the products or on the preparation method used. The highest diffused active material quantity and the diffusion constant were found to be 3–4 times higher than in case of the pure GEM. The significant differences in the values of the diffusion rate were constant.

![Fig. 6. *In vitro* membrane diffusion results on SDs in SGM](image1)

![Fig. 7. *In vitro* membrane diffusion result on SDs in SIM](image2)

Therefore, the linear part (between 30 and 90 min) of the curves was used to calculate the diffusion rate constants ($K_d$), where (1:2 and 1:3) ratio were recorded higher amount diffusion of GEM with DIMEB comparing with the original drug. On the basis of the dissolution and membrane diffusion results, the active agent content and the degree of solubility increase, I selected 1:2 kneaded products, which were incorporated in solid dosage forms (tablets and capsules).

**Thermoanalytical, FT-IR, X-ray and $^1$H NMR results**

1. The DSC examinations demonstrated a phase transitions more or less in all complexes of different preparative methods, showing an exo/endo peaks related to a crystalline/amorphous transition with different amount of adsorbed water.

2. The X-ray powder diffraction data can explain the nature of the host-guest interactions in crystalline CD inclusion compounds. The changes in the powder crystallinity of the samples were studied by comparing their diffraction patterns. The peaks relating to the crystalline GEM are to be found in the X-ray diffractogram, with
lower intensities as compared with those of GEM itself, in accordance with the active agent content of the product.

3. The findings from the FT-IR spectra confirmed the existence of intermolecular bonding between GEM and the hosts, with significant shifts of the absorption band lines. The different ratios used in the complexes formation greatly influenced the solubility of GEM.

4. True inclusion complex formation was confirmed by $^1$HNMR investigation. It was established that there were chemical bonds between the aromatic ring part (the most non-polar part) incorporated in the cavity of the CD molecule. The methyl protons from the long side-chain and the aromatic proton para to the side-chain are mostly incorporated into the CD.

*Powder technological characterization studies*

Evaluation of the rheological behavior of GEM + DIMEB powders was of great importance, particularly that needed for tablets or capsules production, and it was also necessary to determine the preliminary compression behavior of the complex affording the best results GEM + DIMEB as preformulated product in new tablets or capsules preparations of GEM.

*Particle size analysis and wetting angle results*

The powder characterization on the particles size analysis were determined the particles were mainly spherical; their size varied in only a narrow range; the average size was 2–4 μm; the number of bigger particles was extremely low.

Significantly lower wetting angles were measured for the DIMEB-containing products as compared with the pure GEM. These results were affected by changes of the composition, and also the preparation methods (see Table 3).

<table>
<thead>
<tr>
<th></th>
<th>2:1</th>
<th>1:1</th>
<th>1:2</th>
<th>1:3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PM</strong></td>
<td>27.6</td>
<td>± 2.2</td>
<td>41.5</td>
<td>± 2.2</td>
</tr>
<tr>
<td><strong>KP</strong></td>
<td>16.5</td>
<td>± 3.3</td>
<td>24.3</td>
<td>± 4.5</td>
</tr>
<tr>
<td><strong>US</strong></td>
<td>44.8</td>
<td>± 7.6</td>
<td>25.0</td>
<td>± 1.6</td>
</tr>
<tr>
<td><strong>GEM</strong></td>
<td><strong>64.8</strong></td>
<td><strong>± 0.2</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Morphological study

SEM (scanning electron microscope) investigated the morphological properties of the pure GEM, DIMEB and SDs, where the GEM (Fig. 8/a) consists of crystals with mainly a columnar form and a broad size distribution. The edges of the columnar crystals are rounded. The surface of these crystals is generally smooth, but in some places small particles can be seen on it. Therefore, such small crystals occur among the larger crystals. The picture of DIMEB (Fig. 8/b) demonstrates a product with heterodisperse particles. The product consists of irregularly shaped, differently sized particles. The spray-drying method is a good one for preparing products with better rheological properties (Fig. 8/c, SDs 1:1). These products have small is dimensional particles, which is important in the formulation of solid dosage forms. The particle size is different, but its surface is smooth.

![8/a](image1) ![8/b](image2) ![8/c](image3)

Fig. 8. SEM photograph of GEM (a), DIMEB (b) and SD 1:1 product (c)

Table and capsule test result

Results of the tablet and capsule tests are shown in Table 4.

<table>
<thead>
<tr>
<th>Examinations</th>
<th>Tablet</th>
<th>Capsule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average mass (mg)</td>
<td>177.24</td>
<td>227.22</td>
</tr>
<tr>
<td>Uniformity of mass (mg)</td>
<td>± 4.3</td>
<td>± 4.5</td>
</tr>
<tr>
<td>Height (mm)</td>
<td>3.172</td>
<td>Std. 0.019</td>
</tr>
<tr>
<td>Diameter (mm)</td>
<td>9.074</td>
<td>Std. 0.024</td>
</tr>
<tr>
<td>Friability (%)</td>
<td>0.258</td>
<td>Std. 0.035</td>
</tr>
<tr>
<td>Breaking hardness (N)</td>
<td>49.0</td>
<td>Std. 6.782</td>
</tr>
<tr>
<td>Disintegration time (s) in SGM</td>
<td>220.72</td>
<td>78.58</td>
</tr>
<tr>
<td></td>
<td>165.66</td>
<td>37.68</td>
</tr>
<tr>
<td>Disintegration time (s) in SIM</td>
<td>199.17</td>
<td>53.02</td>
</tr>
<tr>
<td></td>
<td>143.33</td>
<td>61.02</td>
</tr>
</tbody>
</table>
**Dissolution profiles of tablets and capsules**

To summarize the dissolution data, we found that the active agent was released relatively quickly, and the dissolution profile from the solid dosage forms depended only slightly on the pH of the acceptor medium (see Fig. 9, 10).

![Fig. 9. Profile of GEM dissolution from tablets](image)

![Fig. 10. Profile of GEM dissolution from capsules](image)

**Membrane diffusion of tablets and capsules**

The *in vitro* membrane diffusion ability of solid dosage forms from SGM and SIM was measured (Fig. 11 and 12).

![Fig. 11. Membrane diffusion of GEM from tablets](image)

![Fig. 12. Membrane diffusion of GEM from capsules](image)
Less drug diffused through the artificial membrane in the case of SGM (tablets: 23% after 150 min; capsules: more than 17%). 38–41% GEM content was measured in the acceptor phase in the case of SIM. A higher standard deviation was experienced for the capsule dosage form.

**SUMMARY**

To summarize the results, it may be conclude that the inclusion complexes formed between GEM and CD derivatives as hosts are of promise as for better future pharmaceuticals. Through their use, there is a possibility to improve the bioavailability of poorly water-soluble drugs, which is important as regards their industrial price, and promising as concerns decrease of the therapeutic dose of the given drug.

**Publications relating to the thesis**

**Papers:**


**Abstracts:**


Posters:


ACKNOWLEDGEMENTS

I am greatly thankful to Prof. István Erős and to Prof. Piroska Révész (former and present Director of Department of Pharmaceutical Technology, University of Szeged), and to Dr. Zoltán Aigner (my supervisor), Prof. M. Kata, Prof. K. Pintye-Hódi, and to Dr. Ildikó Csóka for their helps and great advises.

Also, I would like to express my thanks to my colleagues and to everybody at this Department who had his/her simple touch on my work for their excellent job and assistance.

I am nicely grateful to Prof. György Dombi (Department of Pharmaceutical analysis, University of Szeged) and to Dr. Ottó Berkesi (Department of Physical Chemistry, University of Szeged) for their helps to measurement and analysis my samples.

My gratitude and great appreciation to my Family and Aden University (Faculty of Pharmacy, Yemen) for covering me with their great honest trust.